Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432306 | 0.85 | KEAP1 (0.48) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL235080 | 0.83 | KDM4E (0.65) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL11856358 | 0.80 | KDM4E (0.70) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL10913328 | 0.80 | KDM4E (0.70) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL43407 | 0.78 | HRH3 (0.46) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL9432621 | 0.77 | GLA (0.49) | KDM4ESMN1; SMN2ALDH1A1GLAUSP2 | |
| SCHEMBL3947071 | 0.77 | DRD2 (0.34) | KDM4ESMN1; SMN2ALDH1A1KEAP1 | |
| SCHEMBL42959 | 0.76 | HRH3 (0.50) | SMN1; SMN2ALDH1A1SIGMAR1POLB | |
| SCHEMBL1998867 | 0.75 | KEAP1 (0.71) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL10569847 | 0.75 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | claimed |
| JP-2011526616-A | — | — | 2011-10-13 | — | — | JP | claimed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | claimed |
| EP-2310010-A2 | CHEMICAL COMPOUNDS 251 | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | claimed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| WO-2010001169-A2 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | WO | claimed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | claimed |
| WO-2008098143-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | WO | claimed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2002064558-A2 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 2002-08-22 | — | — | WO | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | KDM4E 477/4885SMN1; SMN2 3689/4885ALDH1A1 498/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | KDM4E 3228/4885SMN1; SMN2 114/4885ALDH1A1 1429/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | KDM4E 2551/4885SMN1; SMN2 1893/4885ALDH1A1 1159/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | KDM4E 4460/4885SMN1; SMN2 3910/4885ALDH1A1 1135/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | KDM4E 4519/4885SMN1; SMN2 252/4885ALDH1A1 3383/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | KDM4E 3498/4885SMN1; SMN2 1621/4885ALDH1A1 3792/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | KDM4E 478/4885SMN1; SMN2 4014/4885ALDH1A1 683/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | KDM4E 1236/4885SMN1; SMN2 3260/4885ALDH1A1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.